Safety and clinical activity of ipilimumab in melanoma patients with brain metastases

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2011 • 4,304 citations

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 • 3,044 citations

Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System

2004 • 1,678 citations

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

2009 • 1,139 citations

CNS immune privilege: hiding in plain sight

2006 • 737 citations

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

2007 • 612 citations

Immunostimulatory monoclonal antibodies for cancer therapy

2007 • 596 citations

Prognostic factors in 1,521 melanoma patients with distant metastases.

1995 • 567 citations

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

2009 • 551 citations

Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma

1998 • 548 citations

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

2010 • 501 citations

Prognostic factors for survival in melanoma patients with brain metastases

2010 • 494 citations

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

2008 • 311 citations

Ipilimumab: controversies in its development, utility and autoimmune adverse events

2009 • 223 citations

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

2008 • 164 citations

The treatment of brain metastases in melanoma patients

2004 • 162 citations

Determinants of survival in patients with brain metastases from cutaneous melanoma

2010 • 158 citations

Diagnosis and Treatment of mela-noma Brain Metastasis: A Literature Review

2009 • 154 citations

Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma

2010 • 132 citations

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.

2010 • 112 citations

Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post‐brain metastases survival

2010 • 96 citations

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

2000 • 82 citations

Complete regression of a previously untreated melanoma brain metastasis with ipilimumab

2010 • 78 citations

Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases

2007 • 34 citations

Multimodality management of brain metastases in metastatic melanoma patients

2007 • 9 citations